Data presented at American College of Rheumatology (ACR) 2020
Due to COVID-19 concerns, many medical congresses are being presented virtually. Virtual congress materials from ACR can be accessed at https://www.rheumatology.org/
TREMFYA PsA
DISCOVER-1: TNF-experience vs naïve subgroups
DISCOVER-2: Collagen turnover Biomarkers
DISCOVER-1&-2: WK-24 Comp indices
DISCOVER-1&-2: Subgroups by BL Characteristics
DISCOVER 1&2: WK-52 Spondylitis
DISCOVER-1&-2: WK-52 Integrated safety
DISCOVER-1&-2: WK-52 FACIT-Fatigue
GUS PSA Network Meta-Analysis
DISCOVER-2 Week 52 S/S/x-ray*
DISCOVER-1&-2 Week24 Enthesitis/Dactylitis*
DISCOVER-2 24-wk- Work Productivity*
DISCOVER-1 Week 52 S/S*
DISCOVER-1 PROMIS-29 validation/Reliability*
DISCOVER-1& -2 Sustained serum biomarker reduction
Modified DISCOVER 2/DLQI (EADV)*
VOYAGE-1&-2 PsA 4yr PsA subgroup*
PsA Real World Evidence
Impact of Fatigue in PsA
Impact of Improving Deteriorating in PsA
Flares in PsA
Impact of Depression in PsA*
Skin involvement in PsA*
Pso PsA Market Scan: Cost of Illness*
Pso PsA Market Scan: Work Disability*
Axial PsA clinical characteristics by HLA-B27 status
SIMPONI ARIA
AWARE: 52 Wk PROMIS SA vs Rem
AWARE: 52 Wk Comparative effectiveness of GLM-IV vs Dose escalated IFX*
STELARA/MA SLE
UST SLE 2001: 2-yr data
UST SLE 2001: Biomarkers
ANTI IFN-I (CNTO6358/JNJ-55920839): Biomarkers
Predictors of SLE diagnosis
Remission, LLDAS, flares
Impact of Remission and LDA on HCRU
Impact of high DA on HCRU, QoL & Productivity*
Impact of flares on HCRU QoL and Productivity*
STELARA PsA
PsABIO: Age groups and efficacy
*ENCORE
